Here are five notes:
1. LAT Pharma is an early-stage biotechnology company developing medicines to treat life-threatening complications of liver cirrhosis.
2. Earlier this year, LAT Pharma had a pre-investigational new drug meeting to discuss a submission for a novel therapy to treat ascites due to liver cirrhosis.
3. NanoAntibiotics acquired LAT Pharma in an all-stock, cashless deal.
4. Following the acquisition, the newly formed company will change its name to BioVie.
5. NanoAntibiotics is a development stage company focused on the discovery, development and commercialization of novel drug therapies.
More articles on GI/endoscopy:
25 patients to sue Baystate Noble Hospital for potential exposure to HCV, HBV & HIV: 4 things to know
Patients with flat adenomas may be at higher risk of multiple lesions: 3 insights
FDA approves 1st CRC screening blood test: 4 notes
